[ad_1]

dublin, March 1, 2024 /PRNewswire/ — The “Acute Heart Failure (AHF) Therapeutics: Global Strategic Business Report” report has been added. ResearchAndMarkets.com Recruitment.

research and market logoresearch and market logo

research and market logo

The global acute heart failure (AHF) treatment drug market has reached its target $2.9 billion By 2030

The global market for acute heart failure (AHF) drugs is estimated to be: 599.7 million USD In 2022, the revised scale will be $2.9 billion By 2030, it will grow at a CAGR of 21.7% over the analysis period 2022-2030.

Cardiac glycosides, one of the segments analyzed in the report, recorded a CAGR of 22.3%; 762.4 million USD By the end of the analysis period. Considering the continued recovery post-pandemic, the growth of the B blocker division will be recalibrated such that his CAGR for the next eight years will be revised to his 25.1%.

The acute heart failure (AHF) market has been significantly impacted by the coronavirus disease (COVID-19) pandemic and the looming global recession. Despite challenges, diuretics and vasodilators remain first-line treatment for AHF, but the efficacy of other known agents for AHF is limited, preventing their widespread use. .

Market insights and trajectories present a complex picture influenced by these factors, with varying degrees of competitive market presence among players across the globe in 2022. Recent market activity reflects continued efforts to expand the size of the AHF market and adapt to the evolving medical landscape. Future market outlook suggests a continued focus on addressing the challenges posed by COVID-19 and economic uncertainty, while exploring opportunities for innovation and growth in AHF therapeutics.

The US market is estimated as follows $163.4 millionMeanwhile, China is projected to grow at a CAGR of 30.4%

The US acute heart failure (AHF) therapeutics market is estimated to be: 163.4 million USD In 2022. ChinaThe market size of the world’s second largest economy is 841.2 million USD By 2030, it will achieve a CAGR of 30.4% over the analysis period 2022-2030.

Other notable geographic markets include: Japan and Canada, are expected to grow by 16.3% and 18.4%, respectively, over the period 2022-2030.At the inner Europe, Germany It is expected to grow at a CAGR of approximately 17.1%.led by countries such as Australia, Indiaand South Koreamarket of Asia Pacific is predicted to reach 433.4 million USD By 2030.

Market overview

  • Insights into the influencer market

  • Global market trajectory

  • market outlook

  • Recent market activity

  • Determining the size of the AHF market

  • Acute heart failure – disease overview and available treatments

  • Diuretics and vasodilators – first-line treatment for AHF

  • Other known drugs for AHF – low efficacy precludes use

  • Acute Heart Failure (AHF) Treatments – Market Share Percentage of Major Global Competitors in 2022 (E)

  • Competitive Market Presence – Strong/Active/Niche/Mediocre (E) for Players Worldwide in 2022

  • The impact of the new coronavirus infection (Covid-19) and the looming global recession

Market trends and drivers

  • Traditional treatments leave significant unmet need

  • A novel treatment that brings a ray of hope

  • Key AHF treatments in the pipeline

  • Serelaxin approaches RELAX-AHF-2 trial results

  • Uraritide – a new drug under development for AHF

  • As the number of drug failures increases, the importance of prevention increases.

  • Other promising drugs in development

  • research result

  • Renal insufficiency – predictor of acute heart failure

  • Genetic influences on heart disease in African Americans

  • Elevated BMI – an important risk factor for AHF

  • Supplemental oxygen therapy is not applicable to all cases of AHF

  • Drivers of macro growth

  • Alarming levels of cardiovascular disease (CVD) prevalence: a key growth driver for AHF therapeutics

  • The rapidly growing elderly population: a key growth driver for AHF treatment

Focus on carefully selected players (Total of 93 items posted)

  • Bayer AG (Germany)

  • Bristol-Myers Squibb Company (united states of america)

  • Cardiolentis AG (Switzerland)

  • CVie Therapeutics Limited (Taiwan)

  • Cytokinetics Co., Ltd. (united states of america)

  • Merck & Co. (USA)

  • Novartis AG (Switzerland)

  • Orion Co., Ltd. (Finland)

  • PhaseBio Pharmaceuticals, Inc.united states of america)

For more information about this report, please visit https://www.researchandmarkets.com/r/8td2mb.

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source of international market research reports and market data. We provide the latest data on international and regional markets, key industries, top companies, new products and latest trends.

Media contact:

research and market
Laura WoodSenior Manager
press@researchandmarkets.com

For Eastern Standard Time office hours, please call +1-917-300-0470.
For USA/Canada Toll Free +1-800-526-8630
For GMT office hours, please call +353-1-416-8900.

US Fax: 646-607-1907
Fax (outside the US): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SisionSision

Sision

View original content: https://www.prnewswire.com/news-releases/global-acute-heart-failure-ahf-therapeutics-research-report-2022-2024-and-2030-conventional-therapies-leave- considerable-unmet-needs-novel-treatments-offer-a-ray-of-hope-302077415.html

Source Research and Market

[ad_2]

Source link